© Reuters.
By Gina Lee
Investing.com – Asia Pacific stocks were down on Tuesday morning, even as Australia released.
Japan’s slid 1.28% by 9:02 PM ET (2:02 AM GMT), re-opening after a holiday. South Korea’s was down 0.44%.
In Australia, the fell 0.85%, with growing 7.3% month-on-month in November. The was AUD9.423 billion.
Hong Kong’s was down 0.50%.
China’s edged down 0.12% and the was down 0.29%. The country will release its and price indexes on Wednesday.
Investors continue to monitor the impact of central banks’ tightening of their monetary policies and the spread of the omicron COVID-19 variant.
“We think eventually this market will shift back toward growth, but we still got some wood to chop there; the valuations haven’t corrected,” RBC Capital Markets head of U.S. equity strategy Lori Calvasina told Bloomberg.
“This is a repricing, it’s painful, it has a little bit more ways to go.”
The U.S. Treasury curve flattened, with short-dated yields climbing sharply as bets of a U.S. Federal Reserve interest rate hike in March 2022 increased and Goldman Sachs Group Inc. predicted four hikes in 2022, starting that month.
U.S. Federal Reserve Chairman Jerome Powell said the U.S. economy was expanding at a fast pace, and the central bank will prevent higher inflation from becoming entrenched, ahead of the Senate confirmation hearing for his re-nomination later in the day. Powell also cautioned that the post-COVID-19 economy could look different from the previous expansion.
The U.S. Senate Banking Committee will also hold a hearing for Fed vice-chair nominee Lael Brainard on Thursday. Other Fed officials due to speak later in the day are Kansas City Fed President Esther George and St. Louis Fed President James Bullard.
On the data front, the U.S. will release the and the on Wednesday, followed by the on Thursday.
Giving investor sentiment a boost, however, New York’s virus infections may have reached a peak around a month after the first omicron case was identified in the area. Pfizer Inc. (NYSE:) is also developing a hybrid vaccine that shields against the omicron variant and a new study from Imperial College London showed protective immune “t-cells” triggered by the common cold lessened the chances of contracting COVID-19.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
